Cybin (TSE:CYBN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Cybin Inc. has reported promising results from its Phase 2 study of CYB003, showing significant long-term efficacy in treating major depressive disorder with 100% of participants responding to treatment and 71% achieving remission after 12 months. The study highlights CYB003’s robust and durable effects, showing a 23-point reduction in depression scores and a strong safety profile.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
